Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

All products: general benefit

Other products in the same Health Canada class (N04B) — coverage varies; not interchangeable

  • Entacapone (Comtan): limited Use 367

Pramipexole · DIN 02309157 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02309157 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-11-23 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79475 · Verify on the e-Formulary ↗ (DIN 02309157)

Source record
DIN 02309157: Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id SIV Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79475
Interchangeable products
Act Pramipexole · DIN 02297337 · $0.3901 Apo-Pramipexole · DIN 02292408 · $0.3901 Auro-Pramipexole · DIN 02424118 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02367645 · $0.3901 Sandoz Pramipexole · DIN 02315297 · $0.3901
Shortage status: resolved shortage (ended 2018-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309157
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL 28:92 Miscellaneous Central Nervous System Drugs

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

MEMANTINE HCL

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MIRAPEX (pramipexole dihydrochloride monohydrate) is indicated for adults, as: • treatment of the signs and symptoms of idiopathic Parkinson’s disease. MIRAPEX may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. • symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome. The effectiveness of MIRAPEX used for longer than 12 weeks has not been systematically evaluated in controlled trials for Restless Legs Syndrome. The physician who elects to prescribe MIRAPEX for an extended time should periodically re-evaluate the long-term usefulness for the individual patient. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): The majority of pramipexole (88%) is cleared via renal secretion. Due to age-related reduction in renal function, the elderly have a slower clearance of pramipexole (approximately 25 – 30% lower). The efficacy and safety appear to be unaffected, except the relative risk of hallucination is h… https://pdf.hres.ca/dpd_pm/00075012.PDF PM date: MAR 20, 2024 Source product: MIRAPEX; DIN 02237145; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.